Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CBT-001
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : V-Capital
Deal Size : $25.4 million
Deal Type : Series B Financing
V-Capital Leads $25M New Round In Ocular Drug Developer Cloudbreak Therapeutics
Details : The funds will be mainly used to promote the clinical phase III of the core product CBT-001, as well as to promote other four ophthalmological drug pipelines that will soon enter clinical phase II.
Product Name : CBT-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 17, 2020
Lead Product(s) : CBT-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : V-Capital
Deal Size : $25.4 million
Deal Type : Series B Financing